Mouse models for lung cancer

Molecular Oncology - Tập 7 - Trang 165-177 - 2013
Min-chul Kwon1, Anton Berns1
1Division of Molecular Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands

Tóm tắt

Lung cancer is a devastating disease and a major therapeutic burden with poor survival rates. It is responsible for 30% of all cancer deaths. Lung cancer is strongly associated with smoking, although some subtypes are also seen in non‐smokers. Tumors in the latter group are mostly adenocarcinomas with many carrying mutations in the epidermal growth factor receptor (EGFR). Survival statistics of lung cancer are grim because of its late detection and frequent local and distal metastases. Although DNA sequence information from tumors has revealed a number of frequently occurring mutations, affecting well‐known tumor suppressor genes and proto‐oncogenes, many of the driver mutations remain ill defined. This is likely due to the involvement of numerous rather infrequently occurring driver mutations that are difficult to distinguish from the very large number of passenger mutations detected in smoking‐related lung cancers. Therefore, experimental model systems are indispensable to validate putative driver lesions and to gain insight into their mechanisms of action. Whereas a large fraction of these analyzes can be performed in cell cultures in vitro, in many cases the consequences of the mutations have to be assessed in the context of an intact organism, as this is the context in which the Mendelian selection process of the tumorigenic process took place and the advantages of particular mutations become apparent. Current mouse models for cancer are very suitable for this as they permit mimicking many of the salient features of human tumors. The capacity to swiftly re‐engineer complex sets of lesions found in human tumors in mice enables us to assess the contribution of defined combinations of lesions to distinct tumor characteristics such as metastatic behavior and response to therapy. In this review we will describe mouse models of lung cancer and how they are used to better understand the disease and how they are exploited to develop better intervention strategies.

Tài liệu tham khảo

10.1016/j.ccr.2012.04.032 10.1182/blood-2011-03-343947 10.1016/j.ccr.2011.04.002 10.1016/j.ccr.2010.12.021 10.1128/MCB.01122-10 10.1593/neo.11652 10.1038/nature10937 10.1038/436642a 10.1101/gad.1516407 10.1038/nature00766 10.1101/gad.2046711 10.1016/j.cell.2012.02.023 10.1038/nprot.2009.95 10.1038/nm.1890 10.1101/gad.947701 10.1038/nrc2192 10.1016/j.ccr.2010.11.033 10.1056/NEJMoa1113205 10.1016/S0002-9440(10)64169-7 10.1038/nm1606 10.1016/S1535-6108(03)00191-0 10.1016/j.cell.2007.03.051 10.1016/S0092-8674(00)81683-9 10.1016/j.cell.2011.02.013 10.1016/j.ccr.2010.08.013 10.1371/journal.pone.0008354 10.1002/bies.201100018 10.1158/0008-5472.CAN-07-3117 10.1101/gad.943001 10.1038/nature06030 10.1038/35074129 10.1055/s-0031-1272873 10.1158/2159-8290.CD-10-0044 10.1158/0008-5472.CAN-12-2001 10.1016/j.cell.2005.03.032 10.1158/0008-5472.CAN-07-2300 10.1073/pnas.0712321105 10.1016/j.cell.2012.02.059 10.3322/canjclin.49.1.8 10.1080/10428190500353133 10.1002/dvg.20396 10.1172/JCI44901 10.1371/journal.pone.0011022 10.1016/S1535-6108(03)00220-4 10.1038/sj.onc.1204837 10.1038/nature08462 10.1158/1535-7163.MCT-11-0884 10.1155/2012/568567 10.1038/nrc2899 10.1172/JCI44871 10.4161/cc.10.16.17012 10.1038/nm.2473 10.1038/ng.2396 10.1038/nature08629 10.1242/dmm.003681 10.1101/gad.1417406 10.1016/j.ccr.2010.05.025 10.1371/journal.pone.0000810 Regales L., 2009, Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer, J. Clin. Invest., 119, 3000 10.1038/nature09557 10.1038/ng.2405 10.1371/journal.pone.0022284 10.1158/0008-5472.CAN-09-4228 10.1126/science.1224676 10.1126/scitranslmed.3002003 10.1101/gad.1526207 10.1038/nbt.1640 10.1158/0008-5472.CAN-11-2786 10.1038/nature05945 10.1073/pnas.0805381105 10.1073/pnas.1207238109 10.1038/nature07260 10.1016/j.ccr.2011.04.019 10.1158/0008-5472.CAN-12-2217 10.1038/ng1490 10.1016/j.ccr.2011.08.007 10.1016/j.cell.2007.11.019 10.1158/2159-8290.CD-12-0108 10.1158/0008-5472.CAN-11-3649 10.1016/0169-5002(95)00418-Z 10.1038/ng2037 10.1172/JCI44165 10.1200/JCO.2010.33.2312 10.1126/science.1073096 10.1007/s00335-012-9410-6 10.1038/nature09881 10.1016/S0093-7754(01)90072-7 10.1038/ncb2428 10.1073/pnas.1112499109 10.1158/2159-8290.CD-11-0073 10.1172/JCI31854 10.1073/pnas.1008366107 10.1371/journal.pone.0002220 10.1007/s10555-012-9406-4 10.1016/S0065-230X(09)02001-6 10.1016/j.cmet.2011.12.015 10.1038/nbt.1595
Thông tin
Thông tin xuất bản

Molecular Oncology

Tập 7

165-177

Thông tin tác giả